期刊文献+

进展期胃癌术后早期腹腔温热灌注化疗疗效的临床研究 被引量:7

Clinical Study on Early Postoperative Hyperthemic Peritoneal Chemoperfusion for Advanced Gastric Cancer
原文传递
导出
摘要 [目的]探讨进展期胃癌术后早期腹腔温热灌注化疗对于改善患者生存率的意义。[方法]159例T3、T4(Ⅱ~Ⅳ期)胃癌手术患者,对比研究腹腔温热化疗组化疗方案(78例)与对照组(81例)术后并发症、复发转移率和3年生存率。[结果]并发症比较:腹腔温热化疗组腹胀及肌酐升高的发生率均显著高于对照组(92.3%vs.14.8%,P<0.05;11.5%vs.1.2%,P<0.05),但治疗后均恢复正常。术后复发转移:腹腔温热化疗组腹膜腔复发转移率显著低于对照组(32.1%vs.54.3%,P<0.05)。腹腔温热化疗组3年生存率显著高于对照组(52.6%vs.32.1%,P=0.003)。[结论]进展期胃癌术后早期进行腹腔温热灌注化疗能够减少腹膜腔复发转移,提高生存率。 [Purpose]To explore the role of early postoperative hyperthermic peritoneal chemoperfusion on improving survival rate for gastric cancer. [Methods] One hundred and fifty nine cases with postoperative gastric cancer T3 or T4 stage were divided into hyperthemic peritoneal chemoperfusion group(78 cases) and control group (81 cases). Complication, recurrence metastasis and 3-year survival rates in two groups were compared. [Results ] The complication of tympanites and increased creatinine in chemotherapy group was more than that in control group(92.3% vs. 14.8%, P〈0.05; 11.5% vs. 1.2%, P〈0.05). These complications all recovered to normal after treatment. The intraperitoneal recurrence rate in chemotherapy group was lower than that in control group (32.1% vs. 54.3%, P〈0.05). Three-year survival rate in chemotherapy group was higher than that in control group (52.6% vs. 32.1%, P=0.003). [Conclusion] Postoperative hyperthermic intraperitoneal chemopeffusion can reduce peritoneal recurrence, metastasis and improve survival rate in gastric cancer.
出处 《中国肿瘤》 CAS 2008年第9期810-812,共3页 China Cancer
关键词 胃肿瘤 药物疗法 腹腔温热灌注 gastric neoplasms drug therapy hyperthermic intraperitoneal peffusion
  • 相关文献

参考文献9

  • 1Roviello F, MalTelli D, de Manzoni G, et al. Prospective study of peritoneal recurrence after curative surgery for gastric cancer[J]. Br J Surg, 2003, 90(9): 1113-1119.
  • 2Yoo CH, Noh SH, Shin DW, et al. Recurrence following curative resection for gastric carcinoma [J]. Br J Surg, 2000, 87(2):236-242.
  • 3Gonzalez-Moreno S.Peritoneal surface oncology:a progress report[J]. Eur J Surg Oncol, 2006, 32(6):593-596.
  • 4Matrai Z, Peley G, Kovacs T. Cytoreductive surgery and intraperitoneal hyperthermie chemopeffusion for peritoneal carcinomatosis caused by recurrent inflammatory myofibroblastic sarcoma: a case report and review of the literature[J]. Orv Hetil, 2006, 147(4) : 147-158,
  • 5Hildebmadt B, Wust P, Ahlerso, et al. The cellular and molecular basis of hyperthermid[J]. Crit Revoncol Hematol, 2002, 43(1):33-56.
  • 6Fujimoto S, Takahashi M, Mutou T, et al. Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma[J].Cancer,1999,85(3):529-534.
  • 7Kim JY, Bae HS. A controlled clinical study of serosa-invasive gastric carcinoma patients who underwent surgery plus intraperitoneal hyperthermo-chemo-purfusion (IHCP) [J]. Gastric Cancer, 2001, 4(1):27-33,.
  • 8Zhu ZG,Tang R.Efficacy and safety of intraoperative peritoneal hyperthemlie ehemotherapy for advanced gastrie eaneer patients with serosal invasion. A long-term follow- up study[J]. Dig Surg, 2006, 23(1-2):93-102.
  • 9Kunisaki CS, ttimada It. Therapeutic outcomes of continuous hyperthermic peritoneal perfusion against advanced gastric cancer with peritoneal carcinomatosis [J]. Hepatogastroenterology, 2006, 53(69):473-478.

同被引文献84

引证文献7

二级引证文献71

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部